AVM
Arch Venture Management Portfolio holdings
AUM
$492M
1-Year Est. Return
38.31%
1 Year Est. Return
+38.31%
AUM
$492M
AUM Growth
+$193M
(+65%)
Holding
11
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
RAPP
1
Rapport Therapeutics
RAPP
$1.44B
| $111M | 22.49% |
3,728,738
|
|
||
2
Beam Therapeutics
BEAM
$2.78B
| $110M | 22.38% |
4,540,132
|
|
||
|
MAZE
3
Maze Therapeutics
MAZE
$1.87B
| $107M | 21.7% |
4,120,053
|
|
||
4
Vir Biotechnology
VIR
$931M
| $73.8M | 14.98% |
12,916,663
|
|
||
5
Lyell Immunopharma
LYEL
$732M
| $44.8M | 9.1% |
2,759,072
+938,438
|
|
||
6
Erasca
ERAS
$1.02B
| $24.1M | 4.9% |
11,055,554
|
|
||
7
Gossamer Bio
GOSS
$833M
| $21.2M | 4.3% |
8,055,916
|
|
||
8
Q32 Bio
QTTB
$36.4M
| $635K | 0.13% |
320,482
|
|
||
|
CERO
9
DELISTED
CERo Therapeutics
CERO
| $114K | 0.02% |
22,389
|
|
||
|
UBX
10
DELISTED
Unity Biotechnology
UBX
| – | – |
-1,004,817
|
|
||
|
VERV
11
DELISTED
Verve Therapeutics
VERV
| – | – |
-2,008,809
|
|